Vimarsana
Biggest News Aggregation in the World

Arc 9 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arc 9 Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arc 9 Trial Today - Breaking & Trending Today

Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC - Vimarsana News

Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC

The development of etrumadenant as a potential treatment option for patients with metastatic castration-resistant prostate cancer will be discontinued after data from the phase 1/2 ARC-6 trial did not demonstrate a sufficient clinical benefit for etrumadenant plus zimberelimab and docetaxel compared with docetaxel alone.